Effects of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on colon cancer cell resistance to oxaliplatin and its regulation of microRNA-137

Figure 1 The expression of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 and microRNA-137 in colon cancer. A: Opa-interacting protein 5 antisense RNA 1 (OIP5-AS1) was highly expressed in cancer tissues; B: miR-137 showed low expression in cancer tissues; C: The expression of OIP5-AS1 was negatively correlated with that of miR-137 in cancer tissues (r = - 0.7123); D: The value of OIP5-AS1 in diagnosing colon cancer (CC) patients; E: The value of miR-137 in diagnosing CC patients; F: The expression of OIP 5-AS1 in CC cell lines was much higher than that in the normal colon epithelial cell line; G: The expression of miR-137 in CC cell lines was significantly lower than that in the normal colon epithelial cell line. ^bP < 0.01, ^eP < 0.001 for between-group comparisons. OIP5-AS1: Opa-interacting protein 5 antisense RNA 1; LncRNA: Long non-coding RNA.

Figure 2 Influence of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on the biological function of colon cancer cells. A: The Opa-interacting protein 5 antisense RNA 1 expression in transfected colon cancer cell lines; B: Comparison of proliferation activity of HCT116 cells among different groups after transfection; C: Comparison of cell proliferation activity of SW480 cells among different groups after transfection; D: Comparison of invasion ability among different groups after transfection; E: Comparison of migration ability among different groups after transfection; F: Comparison of apoptosis ability among different groups after transfection, and apoptosis map; G: Comparison of apoptosis-related proteins among different groups after transfection and protein map. ^aP < 0.05, ^bP < 0.01, ^eP < 0.001 for between-group comparisons. OIP5-AS1: Opa-interacting protein 5 antisense RNA 1; LncRNA: Long non-coding RNA; OD: Optical density.

Figure 3 Effects of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on colon cancer cell resistance to oxaliplatin. A: Determined Opa-interacting protein 5 antisense RNA 1 expression in constructed drug-resistant cell lines; B: Effects of oxaliplatin (L-OHP) at different concentrations on growth inhibition of HCT116 and HCT116/L-OHP cells; C: Effects of L-OHP at different concentrations on growth inhibition of SW480 and SW480/L-OHP cells; D: Effects of L-OHP at different concentrations on growth inhibition of HCT116/L-OHP cells in each group after transfection; E: Influence of L-OHP at different concentrations on growth inhibition of SW480/L-OHP cells in each group after transfection; F: Comparison of apoptosis rate of drug-resistant cells among different groups after transfection and apoptosis map; G: Comparison of drug-resistant cell apoptosis among different groups after transfection and apoptotic protein map. SW480/L-OHP indicates SW480 cell line with L-OHP resistance. HCT116/L-OHP indicates HCT116 cell line with L-OHP resistance. ^aP < 0.05, ^bP < 0.01, ^eP < 0.001 for between-group comparisons. OIP5-AS1: Opa-interacting protein 5 antisense RNA 1; L-OHP: Oxaliplatin.

Figure 4 Influence of miR-137 on the biological function of colon cancer cells. A: The miR-137 expression in transfected colon cancer cell lines; B: Comparison of proliferation activity of HCT116 cells among different groups after transfection; C: Comparison of proliferation activity of SW480 cells among different groups after transfection; D: Comparison of invasion ability among different groups after transfection; E: Comparison of migration ability among different groups after transfection; F: Comparison of apoptosis ability among different groups after transfection and apoptosis map; G: Comparison of apoptosis-related proteins among different groups after transfection and protein map. ^aP < 0.05, ^bP < 0.01, ^eP < 0.001 for between-group comparisons. OIP5-AS1: Opa-interacting protein 5 antisense RNA 1; OD: Optical density.

Figure 5 Influence of microRNA-137 on colon cancer cell resistance to oxaliplatin. A: Determined miR-137 expression in constructed drug-resistant cell lines; B: Influence of oxaliplatin (L-OHP) at different concentrations on growth inhibition of HCT116/L-OHP cells in each group after transfection; C: Effects of L-OHP at different concentrations on growth inhibition of SW480/L-OHP cells in each group after transfection; D: Comparison of apoptosis rate of drug-resistant cells among different groups after transfection and apoptosis map; E: Comparison of apoptotic protein of drug-resistant cells among different groups after transfection and apoptotic protein map. SW480/L-OHP indicates SW480 cell line with L-OHP resistance. HCT116/L-OHP indicates HCT116 cell line with resistance L-OHP resistance. ^aP < 0.05, ^bP < 0.01, ^eP < 0.001 for between-group comparisons. L-OHP: Oxaliplatin; miR-NC: MiR negative control; OIP5-AS1: Opa-interacting protein 5 antisense RNA 1.

Figure 6 Effects of Opa-interacting protein 5 antisense RNA 1 on the expression of miR-137 in oxaliplatin-resistant colon cancer cell lines. A: Binding sites between OIP 5-AS1 and miR-137 and dual luciferase reporter assay; B: Verification of the relation between Opa-interacting protein 5 antisense RNA 1 and miR-137 by the RIP assay; C: The miR-137 expression in drug-resistant cell lines after co-transfection; D: Growth inhibition of HCT116/oxaliplatin (L-OHP) cell lines after co-transfection; E: Growth inhibition of SW480/L-OHP cell lines after co-transfection; F: Comparison of apoptosis rate of cell lines among different groups after co-transfection; G: Comparison of apoptosis protein level in drug resistant cell lines among different groups after co-transfection; H: Apoptosis of drug-resistant cell lines in each group after co-transfection; I: Apoptosis-related protein in drug-resistant cell lines in each group after co-transfection. SW480/L-OHP indicates SW480 cell line with L-OHP resistance. HCT116/L-OHP indicates HCT116 cell line with L-OHP resistance. ^bP < 0.01, ^eP < 0.001 for between-group comparisons. L-OHP: Oxaliplatin; miR-NC: MiR negative control; Wt: Wild type; Mut: Mutant.